News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

immatics biotechnologies GmbH Wins 29th German Industry's Innovation Award


1/26/2009 1:43:03 PM

Tuebingen, January 26, 2009 - immatics biotechnologies GmbH today announced that it has been awarded the 29th German Industry's Innovation Award (Innovationspreis der deutschen Wirtschaft) in the „Start-Up“ category.

immatics was chosen for the award from a list of over 350 applicants covering all industry sectors. The jury consisted of renowned industry professionals and scientists. Relevant selection criteria included project concept, degree of innovation, market success or market opportunities, innovation management, perspectives for additional applications and synergies, cost effectiveness, and benefits for the society and the environment.

This year's award ceremony took place on January 24 at Alte Oper in Frankfurt/Main. The Innovation Award under the patronage of the German Federal Ministry for Economics and Technology is organized by the Wirtschaftsclub Rhein-Main e.V. and the magazine WirtschaftsWoche. Paul Higham, Harpreet Singh, Toni Weinschenk, and Niels Emmerich of immatics biotechnologies received the award from Dr. Annette Schavan, Federal Minister for Education and Research. More than 2500 invited industry representatives, scientists and politicians attended the award ceremony.

“We are delighted to have been awarded the Innovationspreis der deutschen Wirtschaft”, said Paul Higham, Chief Executive Officer of immatics. “This prestigious award is an important appreciation of the potential of our cancer vaccine concept, while at the same time acknowledging the efficiency with which we have been able to bring research projects into clinical development.“

About immatics

immatics biotechnologies is an independent biopharmaceutical company dedicated to the development of active immunotherapies against cancer. immatics' therapeutic vaccines are based on multiple tumor-associated peptides (TUMAPs) which specifically stimulate the immune system against cancer cells. Its lead products - IMA901 for the therapy of renal cell cancer and IMA910 for the treatment of colon cancer - are currently investigated in international phase II clinical studies. Since its foundation in 2000, immatics has raised more than €54 million (US$ 72million) in private equity in two financing rounds. The company has a headcount of more than 65 people and is based in Tuebingen and Munich, Germany.

For additional information please visit www.immatics.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES